GLP-1 Microdosing Chart

What low-dose semaglutide and tirzepatide schedules look like.

By GLP Index editorial Updated July 16, 2026
Microdosing is off-label. There is no FDA-approved microdosing schedule. The ranges below are illustrative examples of what "low-dose" looks like — not a protocol, not a recommendation, and only ever to be done under a clinician's supervision.
Medication

Phase Example weekly dose Notes

A "standard" starting dose (semaglutide 0.25 mg, tirzepatide 2.5 mg) is already a low, tolerance-building dose. Microdosing means starting below that — usually to minimize side effects or for maintenance — and it is not something the drug labels describe.

What “microdosing” actually means

Microdosing a GLP-1 means using a dose lower than the drug’s standard starting dose — and since those starting doses are already the lowest ones the label describes, a microdose is by definition off-label. The chart above shows what illustrative low-dose ranges look like for semaglutide and tirzepatide, so you can see how far below “normal” a microdose sits.

It helps to anchor on the real numbers. The FDA-label starting doses — semaglutide 0.25 mg and tirzepatide 2.5 mg — are already deliberately low, chosen to build tolerance rather than to produce results. Microdosing goes below even those. That’s why the single most common question, “is 2.5 mg of tirzepatide a microdose?”, has a clear answer: no — 2.5 mg is the standard first step everyone starts on.

Why people do it

There’s no approved use for microdosing, but the reasons people try it are consistent:

  • To minimize side effects. Some people are extremely sensitive to the nausea and GI effects and find even the starting dose hard. A slower, lower on-ramp can help them stay on the drug.
  • To maintain results on less. After reaching a goal weight, some want the smallest dose that holds their appetite in check rather than staying at a full maintenance dose.
  • To stretch supply. When the drugs are expensive or hard to get, lower doses last longer — though this is the shakiest rationale medically.

What the evidence says

Here’s the honest part: the evidence for microdosing is thin. The pivotal trials studied the standard titration schedules, not sub-starting doses, so we don’t have good data on how much weight loss or metabolic benefit a true microdose delivers. It’s plausible that lower doses do proportionally less — appetite suppression is dose-related — but “plausible” isn’t “proven.” Anyone telling you a specific microdose schedule is optimal is going beyond what the research supports.

If you’re considering it

Microdosing lives entirely in off-label territory, which means the tested guardrails don’t apply and a clinician’s judgment matters more, not less. The illustrative ranges in the chart are there to show what “below the starting dose” looks like — they are not a protocol to follow on your own. If you and your prescriber decide a lower-and-slower approach fits you, they can build a schedule around your tolerance and goals.

Compounded products are often involved in microdosing because vials allow fine dose adjustments a fixed-dose pen can’t. Remember that compounded GLP-1s are not FDA-approved for safety, effectiveness, or quality, and use the dose calculator to convert any prescribed microdose into accurate syringe units. This tool is educational, not medical advice.

FAQ

Common questions

What counts as a microdose of a GLP-1?

There's no official definition, but in practice "microdosing" means using a dose below the drug's standard starting dose — below 0.25 mg for semaglutide or below 2.5 mg for tirzepatide. The label starting doses are already low, tolerance-building doses; a microdose is deliberately lower than that.

Is 2.5 mg of tirzepatide a microdose?

No. 2.5 mg is tirzepatide's standard FDA-label starting dose — the normal first step everyone begins on. A tirzepatide microdose would be below that, often in the 0.5–1 mg range. Because it's below the label, it's inherently off-label.

Why do people microdose GLP-1s?

The two most common reasons are to minimize side effects (some people are very sensitive to nausea) and to maintain results on the lowest possible dose after losing weight. Some also do it to stretch a limited or expensive supply. None of these uses are FDA-approved, and evidence for low-dose effectiveness is limited.

Is microdosing safe or approved?

Microdosing is off-label — it isn't described in any GLP-1's FDA labeling, and there's no approved protocol for it. That doesn't automatically make it dangerous, but it does mean you're outside the tested schedules, so it should only be done under a clinician's supervision. The doses shown here are illustrative examples, not a recommendation.

Sources

What this is based on

  1. Wegovy (semaglutide) Prescribing Information — U.S. Food & Drug Administration
  2. Zepbound (tirzepatide) Prescribing Information — U.S. Food & Drug Administration

This tool is for general education only and is not medical advice. It does not set or change a prescribed dose — it reflects information you enter. Compounded medications are not FDA-approved for safety, effectiveness, or quality; always confirm your vial's labeled concentration and your dose with your pharmacy or prescribing clinician before acting on any figure here. Only a licensed provider can decide what's right for you. Medical disclaimer · GLP-1 safety information

Find the right GLP‑1 in 2 minutes

Free · No account · Independent